News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Ripple ordered to turn over financial statements by judge
The SEC and Ripple have a discovery deadline of Feb. 12
Blockworks·2024/02/05 22:58
ENS partners with GoDaddy to enable users to link wallets to domains
It is important to note that ownership of a DNS domain ultimately rests with the registrar
Blockworks·2024/02/05 22:52
Genesis wants to sell $1.3B GBTC
A hearing on the motion will take place on Thursday, Feb. 8
Blockworks·2024/02/05 22:46
New bitcoin ETFs overcome GBTC asset losses, yielding strong inflow week
CoinShares data shows GBTC outflows decreased from $2.2 billion to $927 million week over week, while BlackRock and Fidelity asset gains continue
Blockworks·2024/02/05 22:46
Cryptocurrencies flat, stocks lower as traders accept rate cuts are not coming in March
Investors are questioning how to interpret a dovish Fed and conflicting economic data
Blockworks·2024/02/05 21:56
Bitcoin price still 43K after trading sideways for 2 months
Bitcoin miners are no doubt closely watching fee revenues ahead of the next halving, which is now expected to hit April 20
Blockworks·2024/02/05 21:56
Bitcoin drives digital asset market gains as Grayscale selloff slows
Cointelegraph·2024/02/05 21:55
Solana Investors Flock Back With $13M Inflows Beating Ethereum, Avalanche
Bitcoin received inflows totaling $703 million last week, accounting for 99% of all flows.
Cryptopotato·2024/02/05 21:52
Judge orders Ripple to hand over financial documents after request from SEC
Quick Take A judge granted an SEC motion to compel Ripple to produce 2022-2023 financial statements and contracts governing institutional sales of XRP.
The Block·2024/02/05 20:37
Bitcoin price flirts with $43K, but derivatives data points to traders' low confidence
Cointelegraph·2024/02/05 19:58
Flash
11:45
SpaceX perpetual futures remain effectively priced, while spot token issuance faces setbacks.According to Bloomberg, SpaceX perpetual futures accurately reflected market sentiment and converged to the stock trading range before the Nasdaq opened, but the SpaceX stock tokenization product was ultimately forced to refund as the trading platform failed to obtain enough underlying shares.
11:41
SK Hynix rumored to launch a shareholder return plan worth hundreds of trillions of won, official response: The specific scale has never been discussed.SK Hynix responded to Jiemian News stating that it is "exploring various options to enhance shareholder value, but the company has never discussed specific details such as the scale of shareholder returns mentioned in the relevant reports." Previously, The Korea Economic Daily reported that SK Hynix planned to launch an ultra-large shareholder return policy worth 100 trillion Korean won in the fourth quarter of this year, with specific measures including share buybacks and cash dividends. This move was interpreted by outsiders as a major strategic bet by SK Group Chairman Chey Tae-won, aiming to enhance the company’s position and valuation in the global capital market through large-scale shareholder returns.
11:40
Moderna, Inc. recently revealed that the company is actively planning its future product pipeline, and it is expected that as many as three new vaccine products may be launched between 2027 and 2028.These potential new products include a combined vaccine that protects against both influenza and COVID-19, an updated vaccine for seasonal influenza, and a new vaccine designed to prevent norovirus infection. This plan highlights Moderna’s ongoing expansion and in-depth application of its mRNA technology platform. The company is committed to extending its core mRNA research and development capabilities from the successful response to the COVID-19 pandemic to a broader range of respiratory and even gastrointestinal infectious diseases. If the combined influenza and COVID-19 vaccine is successfully launched, it could simplify public health immunization procedures and provide people with more convenient and comprehensive protection options. The development of a norovirus vaccine marks an important step for the company into a new field of disease prevention.Market analysts have pointed out that if this product pipeline plan progresses smoothly, it could open up new growth opportunities for Moderna in the coming years and strengthen its leading position in the global biotechnology and vaccine sectors. Investors are closely monitoring the progress of these research and development projects as well as their commercialization prospects.
News